AMY2A

Across TCGA pan-cancer cohorts, AMY2A mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated AMY2A data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AMY2A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AMY2A expression acts as an unfavorable survival marker.

PDAC are the cancer types where AMY2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.256	0.417	.010	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

AMY2A–PDAC (DFS)

Open the PDAC breakdown →